JP5478886B2 - 癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系 - Google Patents

癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系 Download PDF

Info

Publication number
JP5478886B2
JP5478886B2 JP2008536843A JP2008536843A JP5478886B2 JP 5478886 B2 JP5478886 B2 JP 5478886B2 JP 2008536843 A JP2008536843 A JP 2008536843A JP 2008536843 A JP2008536843 A JP 2008536843A JP 5478886 B2 JP5478886 B2 JP 5478886B2
Authority
JP
Japan
Prior art keywords
cationic
complex
liposome
tfrscfv
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008536843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512712A5 (https=
JP2009512712A (ja
Inventor
エスター・エイチ・チャン
キャスリーン・エフ・ピロロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of JP2009512712A publication Critical patent/JP2009512712A/ja
Publication of JP2009512712A5 publication Critical patent/JP2009512712A5/ja
Application granted granted Critical
Publication of JP5478886B2 publication Critical patent/JP5478886B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008536843A 2005-10-20 2006-10-20 癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系 Expired - Fee Related JP5478886B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72830305P 2005-10-20 2005-10-20
US60/728,303 2005-10-20
PCT/US2006/041139 WO2007047981A2 (en) 2005-10-20 2006-10-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Publications (3)

Publication Number Publication Date
JP2009512712A JP2009512712A (ja) 2009-03-26
JP2009512712A5 JP2009512712A5 (https=) 2011-03-24
JP5478886B2 true JP5478886B2 (ja) 2014-04-23

Family

ID=37963345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536843A Expired - Fee Related JP5478886B2 (ja) 2005-10-20 2006-10-20 癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系

Country Status (7)

Country Link
JP (1) JP5478886B2 (https=)
KR (1) KR20080064169A (https=)
CN (1) CN101351225B (https=)
AU (1) AU2006304790B2 (https=)
CA (1) CA2638899C (https=)
IL (1) IL190773A (https=)
WO (1) WO2007047981A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2692546C (en) * 2007-07-09 2018-03-13 Esther H. Chang Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
CN111808084A (zh) * 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
RU2427390C2 (ru) * 2009-06-08 2011-08-27 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН Способ неинвазивного качественного и количественного определения магнитоуправляемых нанопрепаратов и оценки их функций в реальном времени у экспериментальных животных
CN102078624B (zh) * 2010-12-23 2012-07-25 华东理工大学 一种高效载钆脂质体制剂及其制备方法
WO2013031619A1 (ja) * 2011-08-26 2013-03-07 学校法人藤田学園 抗ヒトトランスフェリン受容体抗体を含む画像用腫瘍診断剤
EP2711000B1 (en) * 2012-09-19 2019-04-03 Georgetown University Targeted Liposomes
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2901616A1 (en) * 2013-03-14 2014-10-02 Georgetown University Treatment for exposure to nerve agent
EP3790533A1 (en) * 2018-05-08 2021-03-17 University of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
EP3962521A1 (en) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
CN117883382B (zh) * 2023-11-27 2025-02-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971692B1 (de) * 1997-03-07 2003-03-05 Max-Delbrück-Centrum Für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
JP4799736B2 (ja) * 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
PL366025A1 (pl) * 2000-05-03 2005-01-24 Munich Biotech Ag Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach
WO2003084386A2 (en) * 2002-04-03 2003-10-16 See Jackie R Methods for ultrasonic imaging and treating diseased tissues
JP2006517032A (ja) * 2003-01-28 2006-07-13 ジョージタウン・ユニバーシティ ある種の癌治療の有効性を評価するための方法
DK1633327T3 (da) * 2003-06-04 2010-11-15 Univ Georgetown Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekser
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
JP2005170807A (ja) * 2003-12-09 2005-06-30 Fuji Photo Film Co Ltd 抗体を含むリポソーム

Also Published As

Publication number Publication date
KR20080064169A (ko) 2008-07-08
CN101351225A (zh) 2009-01-21
CA2638899A1 (en) 2007-04-26
IL190773A (en) 2012-06-28
WO2007047981A3 (en) 2007-10-25
AU2006304790A1 (en) 2007-04-26
CN101351225B (zh) 2013-09-25
WO2007047981A2 (en) 2007-04-26
CA2638899C (en) 2016-01-05
AU2006304790B2 (en) 2013-06-27
HK1129063A1 (en) 2009-11-20
JP2009512712A (ja) 2009-03-26
IL190773A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
US20140178296A1 (en) Tumor-targeted nanodelivery systems to improve early mri detection of cancer
EP2641616B1 (en) Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry
IL190773A (en) Antibody or antibody fragment-targeted cationic immunolysome complex and methods of preparing the same
Mulder et al. Lipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging
ElBayoumi et al. Current trends in liposome research
Kozlowska et al. Molecular and magnetic resonance imaging: The value of immunoliposomes
US9956175B2 (en) Nanoparticles delivery systems, preparation and uses thereof
JP4987474B2 (ja) リポソーム複合体の安定性および使用期限を改良するための方法
US8361494B2 (en) Biomimetic iron-oxide-containing lipoprotein and related materials
Cheong et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system
US10064962B2 (en) Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
US9211346B2 (en) Carrier-linked magnetic nanoparticle drug delivery composition and method of use
JP2004535407A (ja) 標的化多価高分子
Juul et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
WO2013019137A1 (en) Oxide ferrimagnetics with spinel structure nanoparticles and iron oxide nanoparticles, biocompatible aqueous colloidal systems comprising nanoparticles, ferriliposomes, and uses thereof
Iqbal et al. Small unilamellar vesicles: a platform technology for molecular imaging of brain tumors
Su et al. In vivo magnetic resonance and fluorescence dual-modality imaging of tumor angiogenesis in rats using GEBP11 peptide targeted magnetic nanoparticles
Karathanasis et al. MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in rat glioma
HK1129063B (en) Tumor-targeted nanodelivery systems to improve early mri detection of cancer
Meenu Polymeric and inorganic nanoparticles for cancer treatment and diagnosis
Kozlowska Application of targeted contrast nanoparticles for human multiple myeloma imaging
Alawak Immuno Magnetic Thermosensitive Liposomes For Cancer Therapy
HK1188147B (en) Method for improving stability and shelf-life of liposome complexes

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140212

R150 Certificate of patent or registration of utility model

Ref document number: 5478886

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees